Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : Announces Agreement with Thermo Fisher Scientific for Fill/Finish Manufacturing of Moderna's COVID-19 Vaccine

06/02/2021 | 09:10am EDT

CAMBRIDGE, Mass. - Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that it has entered into an agreement with Thermo Fisher Scientific (NYSE: TMO) for fill/finish sterile manufacturing services and supply packaging for Moderna's COVID-19 vaccine.

Under the terms of the agreement, Thermo Fisher's commercial manufacturing site in Greenville, North Carolina will be used for aseptic fill/finish, labeling and packaging to support the production of hundreds of millions of doses of the Moderna COVID-19 vaccine. Production will begin in the third quarter of 2021.

'Thermo Fisher has been a critical partner in supplying raw materials for our COVID-19 vaccine and we are now pleased to further expand our relationship as an important manufacturing partner as well,' said Juan Andres, Moderna's Chief Technical Operations and Quality Officer. 'The addition of Thermo Fisher to our network will support our efforts to scale up our manufacturing ability.'

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 24 development programs are underway across these therapeutic areas, with 14 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding Moderna's development of a vaccine against SARS-CoV-2 (mRNA-1273), and an arrangement pursuant to which Thermo Fisher Scientific will provide fill/finish sterile manufacturing services, as well as labeling and packaging for the Moderna COVID-19 Vaccine, and the timing and scale for those services. In some cases, forward-looking statements can be identified by terminology such as 'will,' 'may,' 'should,' 'could,' 'expects,' 'intends,' 'plans,' 'aims,' 'anticipates,' 'believes,' 'estimates,' 'predicts,' 'potential,' 'continue,' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the safety, tolerability and efficacy profile of the Moderna COVID-19 Vaccine observed to date may change adversely in ongoing analyses of trial data or subsequent to commercialization; the Moderna COVID-19 Vaccine may prove less effective against variants of the SARS-CoV-2 virus, or the Company may be unsuccessful in developing future versions of its vaccine against these variants; despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with the Company's regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; Moderna may encounter delays in meeting manufacturing or supply timelines or disruptions in its distribution plans for the Moderna COVID-19 Vaccine; whether and when any biologics license applications and/or additional emergency use authorization applications may be filed in various jurisdictions and ultimately approved by regulatory authorities; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading 'Risk Factors' in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof.




Colleen Hussey

Director, Corporate Communications

T: 617-335-1374

E: Colleen.Hussey@modernatx.com


Lavina Talukdar

Head of Investor Relations

T: 617-209-5834

E: Lavina.Talukdar@modernatx.com

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -2.19% 328.5 Delayed Quote.214.44%
THERMO FISHER SCIENTIFIC 0.22% 530.28 Delayed Quote.13.60%
All news about MODERNA, INC.
02:37aMODERNA : Spain's Rovi raises outlook thanks to Moderna vaccine contract
02:05aLegal wrangles hold up U.S. vaccine donations to India
01:48aMODERNA : Expects COVID-19 Vaccine Supply Issues To Persist Outside US
07/27MODERNA : U.S. administers 342.6 mln doses of COVID-19 vaccines - CDC
07/27MODERNA : U.S. CDC Says Delivered 395,460,845 Doses Of COVID-19 Vaccine As Of Ju..
07/27Moderna says COVID-19 vaccine supply outside United States to slow down
07/27PFIZER : FDA asks Pfizer, Moderna to widen trials for COVID-19 vaccines in child..
07/27Manufacturing Woes Plague Shipment of Moderna COVID-19 Jab to South Korea
07/27SINOVAC BIOTECH : Antibodies from Sinovac's COVID-19 shot fade after about 6 mon..
07/27Dassault Systemes lifts 2021 outlook on surging software sales
More news
Financials (USD)
Sales 2021 19 117 M - -
Net income 2021 10 725 M - -
Net cash 2021 11 948 M - -
P/E ratio 2021 13,0x
Yield 2021 -
Capitalization 132 B 132 B -
EV / Sales 2021 6,27x
EV / Sales 2022 6,99x
Nbr of Employees 1 300
Free-Float 90,3%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 328,50 $
Average target price 179,20 $
Spread / Average Target -45,4%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.214.44%131 902
LONZA GROUP AG20.01%55 520
CELLTRION, INC.-26.60%31 131
SEAGEN INC.-17.54%26 209